WORCESTER, Mass.--(BUSINESS WIRE)--June 6, 2006--Biovest International, Inc. (OTCBB: BVTI - News) has filed for regulatory approval to open up to 30 new clinical sites for its pivotal Phase 3 trial of BiovaxID(TM) for the treatment of follicular non-Hodgkin's lymphoma (NHL) -- a major milestone for the Company. The opening of these sites is expected to dramatically increase the number of patients being treated with BiovaxID during the next 12 to 18 months. The filings have been submitted by the contract research organizations which will manage the trials for Biovest in Ukraine and Russia and will be responsible for monitoring patient recruitment and overseeing all aspects of the studies.
